No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
KYTX240816P10000
15min DelayTrading
HighLow
--Open--Pre Close-- Volume-- Open Interest--Strike Price--Turnover--IV--PremiumAug 16, 2024Expiry Date--Intrinsic Value--Multiplier24DDays to Expiry--Extrinsic Value--Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
Morgan Stanley Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $40
Leerink Partners Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Announces Target Price $48
Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product
Express News | HC Wainwright & Co. Reiterates Neutral on Kyverna Therapeutics, Maintains $8 Price Target
Kyverna (KYTX) Sees Pre-Market Surge After Regulatory Milestone
Bank Of America, Morgan Stanley And Other 3 Stocks To Watch Heading Into Tuesday
Comments
$Kyverna Therapeutics(KYTX.US$
Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
Kyverna Therapeutics (KYTX) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for KYV-101, its autologous CD19 CAR T-cell therapy, in treating refractory stiff-person syndrome. This designation, based on positive clinical outcomes in Germany, allows Kyverna to receive expert guidance on efficient ...
Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
Kyverna Therapeutics (KYTX) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for KYV-101, its autologous CD19 CAR T-cell therapy, in treating refractory stiff-person syndrome. This designation, based on positive clinical outcomes in Germany, allows Kyverna to receive expert guidance on efficient ...
Read more